Selective Killing of Breast Cancer Cells by Doxorubicin‐Loaded Fluorescent Gold Nanoclusters: Confocal Microscopy and FRET1. Issue 2 (4th December 2015)

• Record Type: Journal Article
• Authors: Chattoraj, Shyamtanu; Amin, Asif; Jana, Batakrishna; Mohapatra, Saswat; Ghosh, Surajit; Bhattacharyya, Kankan
• Is Part Of: Chemphyschem. Volume 17:Issue 2(2016)
• Page Start: 253
• Page End: 259
• Publication Date: 2015-12-04
• Subjects: bioimaging -- cancer -- drug delivery -- FRET -- nanoparticles; Chemistry, Physical and theoretical -- Periodicals; 541.05
• DOI: 10.1002/cphc.201500982
• Languages: English
• ISSNs: 1439-4235

Abstract

Abstract: Fluorescent gold nanoclusters (AuNCs) capped with lysozymes are used to deliver the anticancer drug doxorubicin to cancer and noncancer cells. Doxorubicin‐loaded AuNCs cause the highly selective and efficient killing (90 %) of breast cancer cells (MCF7) (IC50 =155 nm ). In contrast, the killing of the noncancer breast cells (MCF10A) by doxorubicin‐loaded AuNCs is only 40 % (IC50 =4500 nm ). By using a confocal microscope, the fluorescence spectrum and decay of the AuNCs were recorded inside the cell. The fluorescence maxima (at ≈490–515 nm) and lifetime (≈2 ns), of the AuNCs inside the cells correspond to Au10–13 . The intracellular release of doxorubicin from AuNCs is monitored by Förster resonance energy transfer (FRET) imaging. Abstract : Licence to kill : This study shows the real‐time release (delivery) of the anticancer drug doxorubicin from gold nanoclusters (AuNCs) carrier inside cancer and noncancer cells. The use of doxorubicin‐loaded AuNCs leads to the selective killing of breast cancer cells (MCF7), significantly increases the survival rate of noncancer breast cells (MCF10A), and shows strong potential as a breast cancer cell specific therapeutic material with minimal side effects.